Eagle Pharmaceuticals, Inc.
EGRX
$1.90
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 257.55M | 267.04M | 316.61M | 298.23M | 272.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 257.55M | 267.04M | 316.61M | 298.23M | 272.18M |
| Cost of Revenue | 77.68M | 84.48M | 94.94M | 87.38M | 71.99M |
| Gross Profit | 179.88M | 182.56M | 221.67M | 210.85M | 200.20M |
| SG&A Expenses | 102.62M | 94.30M | 88.53M | 83.60M | 80.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 215.95M | 216.04M | 217.55M | 201.64M | 196.93M |
| Operating Income | 41.61M | 51.00M | 99.06M | 96.59M | 75.25M |
| Income Before Tax | 29.17M | 14.00M | 61.43M | 49.35M | 40.36M |
| Income Tax Expenses | 17.22M | 16.67M | 25.79M | 28.07M | 17.57M |
| Earnings from Continuing Operations | 11.95 | -2.67 | 35.64 | 21.28 | 22.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.95M | -2.67M | 35.64M | 21.28M | 22.79M |
| EBIT | 41.61M | 51.00M | 99.06M | 96.59M | 75.25M |
| EBITDA | 62.23M | 67.68M | 111.08M | 104.05M | 79.77M |
| EPS Basic | 0.92 | -0.21 | 2.82 | 1.71 | 1.82 |
| Normalized Basic EPS | 1.74 | 1.91 | 4.36 | 3.90 | 3.30 |
| EPS Diluted | 0.91 | -0.22 | 2.75 | 1.65 | 1.76 |
| Normalized Diluted EPS | 1.73 | 1.90 | 4.31 | 3.85 | 3.25 |
| Average Basic Shares Outstanding | 52.33M | 52.08M | 51.73M | 51.61M | 51.52M |
| Average Diluted Shares Outstanding | 52.60M | 52.28M | 52.03M | 51.81M | 51.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |